

# Clinical & Translational Immunology

Impact Factor 6.464

Cutting-edge advances  
in biomedical research

Editor-in-Chief: Rajiv Khanna

*Clinical & Translational Immunology* is an open access, online-only journal, seeking to cover basic, translational and clinical studies in all aspects of human immunology, including experimental models specific to human diseases.

ASI members enjoy a discount for publishing in *Clinical & Translational Immunology*



Submit your next manuscript to *Clinical & Translational Immunology* and enjoy these benefits of publishing with Wiley



Wiley Open Access



readcube



Altmetric

KUDOS 

ORCID

Find out more at  
[www.wileyonlinelibrary.com/journal/cti](http://www.wileyonlinelibrary.com/journal/cti)

WILEY

# Clinical & Translational Immunology


Catch up on recent Special Features from *Clinical & Translational Immunology*, including:



## CTI Special Feature on Regulation of Immunity and Infection by Pathways of Cellular Metabolism

Special Feature Coordinators: Katrina Binger and Justine Mintern

Immunometabolism is an ever-growing area of research with articles on this topic published in high-impact journals on a regular basis. The promise of this field is that increased understanding of how pathways of cellular metabolism influence the function of immune cells will open novel areas for the manipulation of immunity. However, this poses significant challenges for specificity and toxicity as metabolic pathways are shared by all cells, not only immune cells. This Special Feature highlights review articles that address the complexity and putative benefits of targeting immune cell metabolism to regulate immunity and infection. The Special Feature encompasses diverse areas of immunology, from the interplay between systemic metabolism, immune responses and haematopoiesis, to recent insight into cellular metabolic pathways and molecular processes that influence immune responses to infection.




## CTI Special Feature on Frontiers in Antiviral Therapy and Immunotherapy

Special Feature Coordinator: Steven Heaton

Despite recent advances in the therapeutic control of immune function and viral infection, current therapies are often challenging to develop, expensive to deploy and readily select for resistance-conferring mutants. Shaped by the host-virus immunological 'arms race' and tempered in the forge of deep time, the biodiversity of our world is increasingly being harnessed for new biotechnologies and therapeutics. Simultaneously, a shift towards host-oriented antiviral therapies is currently underway. In this *Clinical & Translational Immunology* Special Feature, the articles outline a strategic vision integrating these themes to create a new generation of effective, economical and robust antiviral treatments and immunotherapies. Durable international cooperation over the coming decades is necessary to achieve this; therefore, in this CTI Special Feature, leading international experts discuss frontiers in host-oriented therapies, methods for modulating immune gene expression and applications of recent genome sequencing technologies, including an emerging research field.

# Clinical & Translational Immunology




## CTI Special Feature on Unconventional immunity: the role of $\gamma\delta$ T cells in host defense and disease

Special Feature Coordinators: Martin Davey and Emily Eriksson

$\gamma\delta$  T cells have been preserved alongside  $\alpha\beta$  T cells and B cells for ~500 million years of vertebrate evolution.  $\gamma\delta$  T cells are increasingly recognised as having important roles in immune responses to both microbial and non-microbial challenges in mice and humans. In this Special Feature of *Clinical & Translational Immunology*, we highlight the role of  $\gamma\delta$  T cells in infectious disease, cancer, transplantation and the lasting contributions of a pioneer of  $\gamma\delta$  T cell research.

(July 2019)



## CTI Special Feature on Cell and Gene Therapy

Special Feature Coordinators: Paul Beavis and Phillip Darcy

Adoptive cellular immunotherapy involving the transfer of autologous chimeric antigen receptor (CAR) T cells has resulted in remarkable responses in relapsed B cell malignancies such as acute lymphoid leukaemia (ALL), often resulting in long-term remission in these patients. These results have led to recent FDA approval of two CAR T cell products for the treatment of CD19+ ALL and non-Hodgkin lymphoma. However, the broad use of this type of therapy for other cancers, in particular solid tumors, has been precluded by both intrinsic and extrinsic factors. This includes the immunosuppressive tumor microenvironment, poor trafficking and infiltration of CAR T cells into the tumor site and heterogeneous expression of antigen on the tumor cells. In this Special Feature of *Clinical & Translational Immunology*, we have invited leading experts in the adoptive immunotherapy field to discuss recent innovative developments for potentially increasing the function, trafficking and safety of CAR T cell therapy and for broadening the utility of this specialised form of immunotherapy for treatment of cancers that have failed conventional treatments.

(March 2019)